<DOC>
	<DOCNO>NCT00084721</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , irinotecan , work different way stop tumor cell divide stop grow die . Celecoxib may stop growth tumor cell block enzymes necessary growth . Giving irinotecan celecoxib may kill tumor cell . PURPOSE : This phase I trial study side effect best dose irinotecan give celecoxib treat patient unresectable metastatic colorectal cancer .</brief_summary>
	<brief_title>Irinotecan Celecoxib Treating Patients With Unresectable Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose irinotecan administer celecoxib patient unresectable metastatic colorectal cancer . Secondary - Determine dose-limiting toxic effect non-dose-limiting toxic effect regimen patient . - Determine incidence intensity diarrhea myelotoxicity patient treat regimen . - Determine response patient treat regimen . - Determine potential mechanism irinotecan-induced diarrhea protective effect celecoxib diarrhea prevention patient treat regimen . OUTLINE : This dose-escalation study irinotecan . Patients assign 1 2 treatment group . - Group I : Patients receive fix dose irinotecan IV 90 minute day 1 , 8 , 15 , 22 oral celecoxib twice daily day 10-42 . Courses repeat every 42 day absence disease progression unacceptable toxicity . - Group II : Patients receive irinotecan group I escalate dos oral celecoxib twice daily day 0-42 . Treatment continue group I . Cohorts 3-6 patient receive escalate dos irinotecan maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 18-30 patient ( 9 group I , 9-21 group II ) accrue study within 1-2 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm colorectal cancer Metastatic unresectable disease Failed firstline secondline therapy OR recur receive fluorouracilbased adjuvant chemotherapy No known brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy More 12 week Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 WBC ≥ 3,000/mm^3 Hepatic AST ALT ≤ 2.5 time upper limit normal Bilirubin normal No Gilbert 's disease Renal Creatinine normal OR Creatinine clearance ≥ 60 mL/min Cardiovascular No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Gastrointestinal Able receive oral medication No prior inflammatory bowel disease No active ulcer disease gastritis No contraindication sigmoidoscopy No active colostomy Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation No prior allergic reaction compound similar chemical biological composition irinotecan , celecoxib , sulfonamide , study agent No active ongoing infection No concurrent uncontrolled illness No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF ) Chemotherapy See Disease Characteristics No 2 prior different chemotherapy regimen , include adjuvant therapy More 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior irinotecan Endocrine therapy Not specify Radiotherapy More 4 week since prior radiotherapy recover No prior radiotherapy 3,000 cGy No prior radiotherapy extended marrowgenerating field No prior abdominopelvic irradiation Surgery No prior abdominoperineal resection Other More 2 week since prior cyclooxygenase2 ( COX2 ) inhibitors No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No anticancer therapy No concurrent COX2 inhibitor Lowdose aspirin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>diarrhea</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
</DOC>